Journal of Current Medical Research and Opinion
Received 18-05-2024 | Revised 19-05-2024 | Accepted 22-06-2024 | Published Online 23-06-2024

DOI: https://doi.org/10.52845/CMRO/2024/7-6-32 ISSN (O) 2589-8779 | (P) 2589-8760

CMRO 07 (06), 2967-2985 (2024)

Original Research

Hemolytic Anemia: Inherited Hemolytic Anemia, Enzyme Defects, Pyruvate Kinase Deficiency, Sickle Cell Anemia, Clinical Symptoms, Diagnosis and Treatment

Nour Mohammed Kadhim Razouki [1], Jinan Nadhim Nimah Daheem Al-Jubouri [2], Ali Jassim Shaker Jassim [3], Samah Sattar Sami Al-Hejazi [4]

[1]University of Babylon - College of Science - Department of Biology, Iraq
[2]University of Babylon - College of Science for Women - Department of Biology, Iraq
[3]University of Babylon - College of Science - Department of Chemistry, Iraq
[4]University of Babylon - College of Science for Women - Department of Biology, Iraq

Abstract:

It is estimated that 42 percent of children under the age of five around the world suffer from anaemia, making it a global health problem. Anaemia is a condition that can be brought on by a variety of various causative factors, as is common knowledge. On the other hand, the pathogenetic mechanisms may be generally classified into three subtypes. These subtypes are a decrease in the synthesis of red blood cells (RBCs), an increase in the loss of RBCs, and an early destruction of RBCs. Two or more of these three mechanisms may overlap. The death of red cells and the release of components found inside the cell are both characteristics of the process known as hemolysis. When a person has hemolytic anaemia, their red blood cells (RBC), which ordinarily have a lifespan of between 100 and 120 days, have a shorter lifespan. Both extravascular and intravascular regions are capable of causing the death of red blood cells (RBC). When it comes to the reticuloendothelial system, macrophages are the cells responsible for extravascular hemolysis. Within the context of clinical practice, it is challenging to differentiate between these two sites of hemolysis. The most significant diagnostic tool is usually the examination of the kid with a whole family history, symptoms, and physical and laboratory results on admission. Although there are vast lists of markers that indicate certain types of hemolysis, the most essential diagnostic tool is always the paediatric evaluation. In addition, the key indicators can be described as the lack of haptoglobin, the presence of hemoglobinuria and hemosiderinuria, and the presence of hemosiderinuria. These are the major markers for intravascular hemolysis. Genetic illnesses known as inherited hemolytic anaemias (IHAs) are characterised by the presence of anaemia as a consequence of the increased destruction of aberrant red blood cells (RBCs) during circulation. Membranopathies, hemoglobinopathies, and enzymopathies are the three primary disorders that are used to categorise the abnormalities experienced by red blood cells (RBCs). Historically, the diagnosis of IHA has been carried out through a sequential method that combines clinical and laboratory results. These days, the aetiology of IHA is thought to be caused by germline mutations of the genes that are responsible for coding for the structural components of red blood cells (RBCs). Recent developments in molecular technologies, such as next-generation sequencing, have inspired us to use these technologies as a first-line method for the discovery of possible mutations and to determine the unique genes that are responsible for the development of IHAs in patients.

Keywords: Inherited hemolytic anemia, Genetic testing, Pyruvate Kinase Deficiency, Sickle Cell Anemia, Symptoms, Diagnosis, Treatment

Introduction:

The term "inherited hemolytic anaemia" (IHA) refers to a wide range of conditions that are genetically and phenotypically distinct from one another. These disorders all arise as a consequence of an increase in the rate at which red blood cells are destroyed. The degree to which this destruction has occurred is directly proportional to the severity of the anaemia or the progression of the beginning of hemolysis. The anaemia that occurs in severe hemolysis can be life-threatening and cause angina and cardiac decompensation. Mild hemolysis, on the other hand, may not cause any significant symptoms. Intrinsic hepatic anaemia (IHA) forms when the red blood cells (RBCs) themselves are faulty. The most prevalent causes of intrinsic HA are defects in haemoglobin (Hb), the membrane of red blood cells (RBC), and the enzymes that are found in RBCs. These defects are typically referred to as hemoglobinopathy, membranopathy, and enzymopathy, respectively [1, 2]. In contrast to the majority of intrinsic HAs, which are hereditary illnesses, paroxysmal nocturnal hemoglobinuria is an uncommon condition. Among the several illnesses that afflict millions of people all over the world, the most prevalent ones are α- and β-hemoglobinopathies, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and hereditary spherocytosis (HS). In a survey-based study conducted by the Korean Institute of Health (IHA), it was shown that 64.0% of cases had RBC membranopathies, 19.9% had hemoglobinopathies, and 13.3% had RBC enzymopathies. RBC morphology, membrane protein analysis [3, 4], Hb electrophoresis, and measurement of RBC enzyme levels have all been part of the conventional method for diagnosing IHA. This method has been used for a long time.

There are times when arriving at an accurate diagnosis of IHA can be difficult. This is due to the fact that the clinical characteristics of instances with diverse aetiologies may overlap, and it is not easy to differentiate between them using the diagnostic methods that are typically used. It is for this reason that there is still a requirement for diagnostic tests that are more sensitive and reliable in order to increase the accuracy of the IHA diagnosis. A genome-wide association study of Hb concentration and related parameters (Hb, mean cell haemoglobin [MCH], mean cell haemoglobin concentration [MCHC], mean cell volume [MCV], packed cell volume [PCV], and RBC) has revealed the possible effects of 75 independent genetic loci on the genetic mechanisms and biological pathways that control RBC formation and function. The study was conducted to investigate the relationship between Hb concentration and these parameters. Extensive research has been conducted to characterise the spectrum of genetic disorders, and genetic testing [5-9] is already available to determine the particular mutation(s) that are associated with IHAs (Table 1). When conventional testing has been unsuccessful or when a patient has undergone extensive transfusions, which can result in confusing biochemical and other testing outcomes due to mixed RBC populations, Sanger sequencing is frequently employed to discover disease-causing mutations. This is done in situations where traditional testing has failed. The most recent technology advancements, such as next-generation sequencing (NGS), have made it possible to conduct a

molecular diagnosis of IHA in a way that is both cost-effective and quick. This is accomplished by doing an exhaustive and simultaneous review of a group of genes that cause the disease.

Table 1. Clinical phenotypes and associated genes in inherited hemolytic anemia.

Clinical phenotypes	Genes	Location	Inheritance
RBC membranopathies			
Hereditary spherocytosis (HS)			
HS type 1	*ANK1*	8p11.21	AD/AR
HS type 2	*SPTB*	14q23.3	AD
HS type 3	*SPTA1*	1q23.1	AR
HS type 4	*SLC4A1*	17q21.31	AD
HS type 5	*EPB42*	15q15.2	AR
Hereditary elliptocytosis (HE)			
HE type 1	*EPB41*	1p35.3	AD
HE type 2	*SPTA1*	1q23.1	AD
HE type 3	*SPTB*	14q23.3	AD
Hereditary pyropoikilocytosis	*EPB41*	1p35.3	AR
	SPTA1	1q23.1	AR
	SPTB	14q23.3	AR
Dehydrated hereditary stomatocytosis 1	*PIEZO1*	16q24.3	AD
Dehydrated hereditary stomatocytosis 2	*KCNN4*	19q13.31	AD
Overhydrated hereditary stomatocytosis	*RHAG*	6p12.3	AD
Southeast Asian ovalocytosis	*SLC4A1*	17q21.31	AD
RBC enzymopathies			
G6PD deficiency	*G6PD*	Xq28	XR
Pyruvate kinase deficiency	*PKLR*	1q22	AR
Enolase deficiency	*ENO1*	1p36.23	AD
Adenylate kinase deficiency	*AK1*	9q34.11	AR
Glucose phosphate isomerase deficiency	*GPI*	19q13.11	AR
Pyrimidine 5′ nucleotidase (UMPH1) deficiency	*NT5C3A*	7p14.3	AR
Gamma-glutamylcysteine synthetase deficiency	*GCLC*	6p12.1	AR
Glutathione peroxidase deficiency	*GPX1*	3p21.31	AR
Glutathione reductase deficiency	*GSR*	8p12	AR
Glutathione synthetase deficiency	*GSS*	20q11.22	AR
Hexokinase deficiency	*HK1*	10q22.1	AR
Bisphophoglycerate mutase deficiency	*BPGM*	7q33	AR
Phosphoglycerate kinase 1 deficiency	*PGK1*	Xq21.1	XR
Triosephosphate isomerase deficiency	*TPI1*	12p13.31	AR
RBC hemoglobinopathies			
β-thalassemia, sickle cell disease	*HBB*	11p15.4	AD/AR
α-thalassemia	*HBA1*	16p13.3	AR
	HBA2	16p13.3	AR

Hemolytic anaemia, in its many forms, is a serious public health issue that affects people all over the world. Hemolytic anaemias can be divided into two categories: those that are acquired and those that are inherited. The acquired forms are typically brought on by the production of autoantibodies that are directed against red cells, whereas the latter forms may be brought on by flaws in the membranes of red cells or by abnormalities in the haemoglobin molecule. On page 6, the constitution of haemoglobin is broken down into its component parts. All hemolytic anaemias share a number of clinical characteristics, which are the result of an increase in the destruction of red cells as well as an increase in the creation of red cells to compensate for the destruction [10-13]. There are signs of anaemia, enlargement of the spleen, the production of gallstones, and test findings that demonstrate

hemolysis (raised unconjugated bilirubin and other characteristics). These symptoms are caused by the accelerated destruction of red cells. Furthermore, the increased production of red cells is represented by a raised reticulocyte count in the blood as well as an increase in erythropoiesis in the bone marrow, which ultimately results in bone abnormalities, particularly in children who have chronic hemolytic anaemias .

Membrane Defects That Are Inherited,
An inherited form of spherocytosis

Hereditary spherocytosis, also known as HS, is the most prevalent form of hereditary hemolytic anaemia among people of northern European heritage who have a 0.02% incidence rate. In the majority of instances, the inheritance pattern is autosomal dominant. There is a loss of membrane lipids and a decrease in osmotic resistance when there is a malfunction in a significant structural protein of the red cell membrane, such as spectrin or other compounds. Recently, the faulty genes that are responsible for spherocytosis have been cloned. These genes include ANKl, EPB3, ELB42, SPTAl, and SPTB. Microspherocytes and other cells with abnormal morphology are phagocytized because they are unable to pass through the splenic microvasculature. Examples of such abnormal morphology include decreased surface area. There is a variability in the severity of the condition. Patients might be dealing with a persistent form of anaemia, or they might be hematologically normal. According to [14, 15], certain people only exhibit symptoms when they are experiencing illnesses or other stressful events. Patients who suffer from anaemia experience persistent weariness, and a significant number of them also experience icteric episodes. Colics are experienced by certain individuals in the right upper abdomen when gallstones are present. When HS is present, the spleen is always enlarged. The presence of aplastic crises in certain patients is a consequence of an infection with parvovirus B19. A severe case of anaemia is the result of a sudden cessation in the formation of red cells, which occurs during a crisis of this nature. There are some people who have HS who have a neonatal icterus that eventually returns to normal. Through the detection of characteristic spherocytes on the blood film (diameter), it is possible to arrive at a diagnosis of HS.

Enzyme Defects That Are Inherited:

A second operation might be required for patients who have undergone a partial splenectomy or who have an auxiliary spleen that grows larger in the event that they experience a recurrence of symptomatic anaemia. It is possible that patients with HS will require blood transfusions and other supportive measures in the event of an acute crisis. There is a possibility that the anaemia will significantly improve if folic acid is substituted.

Inherited Eliptocytosis of the Lungs:

The presence of a sizeable proportion of oval or elliptical red cells on peripheral blood films is one of the characteristics that can be used to identify hereditary elliptocytosis (HE), which is a form of familial hemolytic anaemia. Autosomal dominant inheritance is the mode of inheritance for HE, just as it is for spherocytosis. There is a wide variety of molecular flaws that are implicated, such as mutations in spectrin, protein, or glycophorin C. The majority of patients have a clinical appearance that is mild and does not show any signs of anaemia [16, 17]. In extremely rare instances of homozygosity, where infections have been determined to be associated with an exacerbation of the condition, HE manifests itself as symptoms. Patients who are heterozygous for two distinct mutations (double heterozygosity also known as hereditary pyropoikilocytosis) have a higher risk of developing a severe form of hemolytic anaemia. In the same way that patients with spherocytosis benefit from splenectomy, symptomatic patients with HE also benefit from the procedure.

Enzyme Defects That are Inherited:

A significant number of enzymes are responsible for controlling the glucose metabolism that occurs in red blood cells. Only two forms of enzyme abnormalities are significant in clinical practice: the deficiency of glucose-6-phosphate dehydrogenase (G6PD) and the deficiency of pyruvate kinase (PK). Both of these enzyme defects are found in mitochondria.

Insufficiency of G6PD

The human enzymopathy that is most commonly seen is characterised by deficiencies in the red cell enzyme G6PD. According to some estimates, a deficit of G6PD affects between 5 and 20 percent of the population in several Mediterranean nations, as well as in other Asian and African countries (in some countries, the percentage even reaches 60 percent). The severity of G6PD deficiency will vary from patient to patient, with people from the Mediterranean region typically being found to have a more severe condition than patients from Africa. In Asia, the incidence ranges from 0.1 to 14% of the population. G6PD deficiency affects at least 200 million people around the world. This number is estimated to be higher. The Embden Meyerhof reaction is the initial step in the pentose phosphate pathway, and G6PD is the enzyme that catalyses it. Red cells that are lacking in G6PD have a restricted ability to produce nicotinamide adenine dinucleotide phosphate (NADP) and NADPH (in its reduced form). Considering that they do not possess the ability to reduce, they are susceptible to oxidative stress. Inducing an acute intravasal hemolysis can be accomplished through the use of specific medications, vegetables, and stress situations (see Table 6.2) [18-21]. It has been hypothesised that the presence of certain substances or situations makes it possible for free radicals to be produced .

One of the hereditary recessive disorders that is associated with the X chromosome is known as G6PD deficiency. It is therefore the case that males are the ones who experience the most severe manifestations of the disease, whilst female heterozygotes typically just act as carriers. As a result of the fact that female carriers have the advantage of being protected against malaria, the disease is frequently prevalent in regions where malaria is predominant. It is estimated that there are at least 400 distinct mutations of G6PD. It is possible to differentiate between five different groups of G6PD deficiency based on the degree of enzyme deficiency affected. The individuals are considered to be hematologically normal in between episodes of hemolysis. Following the consumption of fava beans or specific medications, they swiftly develop a severe intravascular hemolysis .

Patients will experience symptoms such as icterus, fever, back discomfort, and hemoglobinuria. Measurement of the enzyme activity in red cells is one method that can be utilised to arrive at a diagnosis of G6PD deficiency. The measurement of the enzyme should not be performed during a hemolytic episode or after a transfusion since doing so will result in an artificially inflated enzyme activity. A screening test that uses a luminous substrate can provide valuable information in a short amount of time for male patients. When the hemolytic episode is occurring, the blood film reveals a large number of broken cells as well as Heinz bodies. Heinz bodies are identified as an intracellular inclusion that may be visualised using a supravital staining. These bodies are composed of haemoglobin that has been oxidised and denatured. Supportive measures are the treatment that is administered in the event of a hemolytic episode [22, 23]. It goes without saying that the elimination of potential stressors is essential, and blood transfusions should be administered if they are required. Patients who have a deficit in G6PD should be protected from any and all potentially harmful drugs with the intention of preventing adverse effects. It is possible for infants who are deficient in G6PD to develop newborn jaundice, which may require them to undergo exchange transfusions and/or phototherapy.

Inadequacy of Pyruvate Kinase Protein:

Autosomal recessive inheritance plays a role in the inheritance of the red cell enzyme PK deficiency. An decreased nicotinamide adenine dinucleotide (NAD) synthesis and a depletion of adenosine triphosphate (ATP) both contribute to an increase in the hemolysis of erythrocytes in this condition. For the most part, heterozygotes do not exhibit any symptoms, but homozygotes suffer from a hemolytic anaemia of varying degrees of severity. At the periphery of the

Diseases of the haemoglobin

The presence of spherocytes, acanthocytes, and echinocytes is conspicuous in the blood smear

samples. The presence of splenomegaly, gallstones, and icterus is frequently seen in patients who are experiencing symptoms. A PK deficit can be diagnosed using screening tests or through the measurement of enzyme activity in the red cells. Both of these methods are available. Infections, similar to those that might occur in other types of chronic hemolytic anaemia, can cause the hemolysis to become even more severe [24, 25]. When it comes to people who are experiencing symptoms and require frequent transfusions, a splenectomy might be advantageous. Infants who are born with a PK deficiency may begin their lives with severe anaemia and frequently require an exchange transfusion.

Alleged Hemoglobinopathies:

The structural abnormalities and the abnormalities that are caused by a reduction in the production of normal (X- or ~-chains of the globin molecule are the two primary categories that are used to classify the genetic abnormalities that are associated with the haemoglobin molecule. Sickle cell anaemia is a model of structural abnormalities, whereas thalassemias are characterised by a decreased synthesis of globin chains. Sickle cell anaemia is a prototype of structural abnormalities. Haemoglobin C disease, haemoglobin E disease, and other illnesses are all caused by structural abnormalities of the haemoglobin molecule called structural abnormalities. Both homozygous and heterozygous versions of each hemoglobinopathy are currently in existence. The homozygous condition is typically the only one in which clinical symptoms exhibit themselves. The condition known as heterozygotes is characterised by the presence of a hemoglobinopathy characteristic.

Anaemia Due to Sickle Cells:

A hemoglobinopathy known as sickle cell anaemia (SCA) is the most prevalent kind of hemoglobinopathy seen all over the world. African countries are the most likely to be affected by this condition, while the Mediterranean region, certain regions of India, and other countries are experiencing a reduced incidence of it. During the sickle mutation, the sixth codon of the -globin gene is altered to contain thymine rather than adenine, which results in the production of valine rather than glutamine. When exposed to low oxygen tension, haemoglobin S (HbS) crystallises into a solid state because it is insoluble. Consequently, this causes changes in the membrane and structure of the erythrocytes, which are referred to as sickling. These changes then obstruct the microcirculation in a number of organs. It is estimated that around one third of the red cells are subjected to intravascular hemolysis, while the reticuloendothelial system of the spleen is responsible for the removal of two thirds of sickle cells, which results in the spleen being larger. Autosomal-codominant inheritance is the mode of transmission for sickle cell anaemia. Those heterozygotes who have a normal enzymatic chain in addition to a problematic enzymatic chain do not exhibit any symptoms. Sickle cell disease is associated with homozygotes. Due to the fact that HbS heterozygotes, which are characterised by sickle cell trait, have an advantage against plasmodial infections [26-29], the geographic distribution of sickle cell anaemia (SCA) is similar to the distribution of plasmodium malariae. It is possible for the sickle cell gene to coexist with other hemoglobinopathies, often known as double heterozygosidad. Patients may be double heterozygotes for HbS and HbC or for HbS and \-thalassemia, for instance. The latter condition is more common. When compared to sickle cell disease, the clinical course of these people is typically less severe.

Clinical Signs and Symptoms:

SCA is characterised by symptoms that are similar to those of severe hemolytic anaemia, including painful crises. The clinical manifestation of homozygous SeA can vary from patient to patient. other patients are able to live a life that is almost normal, while others require blood transfusions or experience periodic severe crises, and other patients may pass away while they are still children. The presence of foetal haemoglobin (HbF) prevents the manifestation of sickle cell anaemia (SCA) during the first six months of a person's life. Among the many variables that can bring about a vaso occlusive crisis are infections,

dehydration, surgical procedures, and other factors. A wide variety of organs and vascular systems may be affected, including the kidneys, the mesenterial circulation, the bones, the lungs, the central nervous system, the spleen, and many more. Stroke occurs in approximately 10% of children who suffer spinal cord injuries, while others have cognitive impairment as a result of subclinical injury to the central nervous system. There is a possibility that the spleen could become atrophic, and patients will be especially vulnerable to infections such as Streptococcus pneumoniae, Haemophilus influenzae, and chronic osteomyelitis caused by Salmonella typhi. When it comes to youngsters, bone infarcts frequently result in growth retardation. Patients who suffer from SCA frequently develop leg ulcers as a consequence of local stasis and a disruption in the microcirculation. Proliferative retinopathy, the development of gallstones, and priapism are some of the other issues that one may experience. A sudden and severe worsening of the anaemia may be caused by a cri sis that involves the sequestration of the spleen. At the moment, the typical life expectancy of people who have SeA is somewhere between forty and fifty years.

The Diagnosis:

The majority of cases exhibit a number of characteristics that are shared by both the clinical presentation and the family history. When compared to the symptoms of anaemia, the value of the haemoglobin is typically quite low. The sickle cells and target cells are visible in the blood smear report. Positive results are obtained from screening tests for sickling, which involve the incubation of red cells under conditions of low oxygen, such as with dithionate. Haemoglobin electrophoresis or polymerase chain reaction (peR) are the two methods that make it possible to arrive at a conclusive diagnosis of sickle cell anaemia (SCA). When homozygous sickle cell disease (SCA) is present, the haemoglobin electrophoresis typically reveals the band of HbS, while the band of normal haemoglobin A (HbA) is not present. The haemoglobin electrophoresis of a healthy individual and that of a sickle cell anaemia patient are both depicted in Figure 6.1. On average, the proportion of HbA and HbS in people who have sickle cell trait is roughly equivalent to one another. There is a possibility that homozygotes for HbS will have a different percentage of HbF 30–35. There is a correlation between cases of SCA that have a higher proportion of HbF (more than 10-15%) and a clinical course that is less severe. MEASUREMENTS OF TREATMENT AND PROPHYLACTIC ACTIONS The treatment for SCA consists primarily of supportive and preventative measures. It is important to steer clear of any and all elements that are known to bring about catastrophes. Infectious diseases should be

In the early stages, hemoglobinopathies are prevented and treated. It is essential to keep one's general health in good condition in order to avoid issues whenever they may arise. Folic acid is another option that is recommended as a replacement. Appropriate analgesia, including morphine, meperidine, codeine, and other medications, should be administered in the event of a sickle cell crisis. Maintaining an adequate level of hydration is essential. In situations where there is a clinical indication, red cell concentrates should be transfused. It is possible that an exchange transfusion is required in the event of difficulties, such as after a stroke or during an emergency situation involving abdominal sequestration. It may be necessary for certain patients who have a severe condition to have chronic transfusions in order to inhibit the generation of HbS. On the other hand, iron overload becomes a significant medical concern in these people. Children who receive blood transfusions have a significantly lower risk of experiencing a subsequent stroke. Children who are at a high risk of getting a stroke can be identified by the use of transcranial ultrasound, and additional transfusions should be administered to these children. A small number of patients with SCA who were considered to be at high risk have been able to successfully undergo allogeneic bone marrow transplantation. At the two to three year mark, around 80–90% of these individuals had survived without experiencing a relapse; nevertheless, additional experience with transplantation is required before general

recommendations can be given. A splenectomy might be necessary for patients who have suffered severe splenic infarctions. Not only is a pneumococcal vaccination and a penicillin prophylaxis recommended for people in this situation, but it is also recommended for patients who have undergone auto splenectomy and have a tiny spleen as a result of multiple splenic infarctions. It is common practice to administer penicillin prophylaxis to children between the ages of two to three months and five years. First, 125 milligrammes twice day for the first three years, and then 250 milligrammes twice daily after that .

For adult patients who suffer from SCA and have numerous painful crises, a new therapy approach known as hydroxyurea has been available for use for a number of years. As well as down-regulating inflammatory responses, hydroxy-urea is responsible for inducing HbF. people who are treated with hydroxyurea experience approximately fifty percent fewer unpleasant occurrences than people who are not treated. At this time, it is unknown whether or not hydroxyurea has the potential to change the long-term prognosis of SCA. The presence of recurrent episodes of pain, a history of acute chest syndrome, other serious vaso-occlusive consequences [36, 37], or severe symptomatic anaemia are all indications that treatment should be administered. A starting dose of 500 milligrammes per day is recommended, and if the blood counts are satisfactory, the dosage can be increased to 1500 milligrammes per day. Furthermore, further novel treatments, such as clotrimazole, magnesium, nitric oxide, and short-chain fatty acids, are now being evaluated for their potential effectiveness .

In adults, the primary haemoglobin molecule consists of four chains, specifically two a-chains and two -chains, which are collectively referred to as haemoglobin A. As a result of the thalassemias, the formation of a normal haemoglobin molecule is prevented because the synthesis of either the a-chain or the -chain is either decreased or absent. In cases of a-thalassemia, the a-chain is either decreased or nonexistent, whereas in cases of -thalassemia, the -chain is either reduced or no longer present. The extra globin chains cause the progenitors of red cells to become denatured, which ultimately results in the death of young cells. Both the clinical manifestation and the severity of the two types of thalassemias (a and ~) are distinct from one another. Individuals of African, Mediterranean, or Asian heritage are more likely to be affected by a-thalassemias, whereas individuals from Southeast Asia are more likely to be affected by -thalassemias .

Both the o-form and the W-form are considered to be the two primary forms of -thalassemia. The o-form does not create any beta chains, whereas the W-form produces a lower quantity of beta chains (l 0-20%). Molecular pathogenesis of -thalassemias is characterised by a wide range of variations. There have been around 150 distinct mutations that have been reported in the -globin gene. The vast majority of lesions are point mutations, and some of them contain short deletions. In the \O-type, the levels of HbF are elevated, HbA is not present, and the concentration of HbA2 varies at different occasions. It has been found that the W-type is linked to elevated HbF levels, a variable quantity of HbA, and normal HbA2 levels. The most severe form of the disease, known as thalassemia major or Cooley's disease, manifests itself in patients who are homozygous. When HbF is regularly replaced by HbA, the clinical symptoms often start to appear between four and six months after birth. The presence of HbF is observed in patients who have -thalassemia [38, 39]. Furthermore, the unbound a-chains carry harmful consequences and result in an inefficient erythropoiesis process. From a clinical standpoint, persons who are homozygous for -thalassemia are characterised by severe hemolytic anaemia and icteric symptoms. Development of a hepatosplenomegaly occurs. The presence of erythroid hyperplasia in the hematopoietic marrow is the cause of the development of bone abnormalities. It is clear that these alterations have occurred in children who have frontal bossing. Because of a decrease in bone density, the bones are more likely to break .

Diseases of the haemoglobin:

It is the cortex. Those youngsters who have -thalassemia are more likely to develop iron overload since they are need to undergo frequent transfusions. They are prone to developing the symptoms of heart failure, also known as hemosiderosis, and have a complexion that is pigmented. Infectious diseases caused by bacteria, viruses, and fungi are quite prevalent, particularly following a splenectomy.

A Laboratory Diagnostic Check

Patients who are diagnosed with -thalassemia are characterised by a hypochromic microcytic anaemia, an increase in reticulocytes together with normoblasts, and target cells in the peripheral blood. An iron overload can be identified by the presence of raised quantities of iron and ferritin in the serum, as well as an enhanced saturation of the iron-binding capacity of the serum. Electrophoresis of haemoglobin reveals that there is either no HbA present or only a faint band of HbA, while the amount of HbF is increased. An increase in haemoglobin A2 (2a2y-chains) is another possibility. PCR or Southern blotting are two methods that can be used to determine the molecular flaw .

Medical Care

Transfusions are required on a frequent basis for patients who have homozygous thalassemia in order to keep their haemoglobin concentration at or above 10 gldL. Due to the fact that chronic transfusions cause an iron overload, it is recommended that patients who are experiencing this condition receive desferoxamine as part of an iron chelation therapy. Table 6.3 provides information regarding the chelation treatment that was administered with desferoxamine. The development of oral chelation agents is now underway. The substitution of folic acid is advantageous for a significant number of people who suffer from -thalassemia. The removal of the spleen may be beneficial for patients who require transfusions on a very regular basis [40, 41]. Refusing to perform a splenectomy on a child until they have reached the age of six is recommended. There should be immediate treatment for any and all infections. A lifelong prophylaxis of penicillin should be administered to patients who have had splenectomy. There have been instances where patients with -thalassemia have successfully had bone marrow or stem cell transplantation from siblings who share the same HLA.

A condition known as hydrops fetalis is the result of the most severe variant, which involves the deletion of all four a-genes. This form is not compatible with life beyond the foetal stage. A somewhat severe form of hypochromic microcytic anaemia, often known as HbH illness, exists when only three chains are removed from the genome. When compared to a-chains, free \-chains do not condense into precipitates but rather assemble into tetramers, which are characterised by their high degree of instability. Red blood cells that possess such aggre gates have a shorter lifespan and are concentrated in the spleen, where they are hemolyzed and sequestered. It is often the case that the hemolysis is adequately compensated for when only one or two a-chain genes are removed. In the majority of instances, the haemoglobin concentration is normal; nevertheless, the red cells tend to be hypochromic and microcytic, which is a characteristic of a-thalassemia. Among the Hemoglobinopathies, Thalassemia Intermedia and Other Conditions Thalas semia intermedia is the terminology used to describe less severe kinds of thalassemia that do not require blood transfusions. Leg ulcers, delayed development, and skeletal abnormalities are some of the most common symptoms that patients with this kind experience. On the other hand, some individuals have a heterozygous p-thalassemia with high levels of HbF, while others have a heterozygous -thalassemia with various globin abnormalities [42, 43]. The cause of thalassemia intermedia is a heterogeneous condition. In West Africa, certain ethnic groups are prone to developing haemoglobin C illness, which is caused by a substitution of an amino acid in the -globin chain among the affected individuals. Patients who are homozygous typically exhibit a moderate form of hemolytic anaemia. Genetic testing for hemoglobinopathies is advised for all women who are members of a

population that is considered to be at a high risk. Using methods such as haemoglobin electrophoresis, the first thing that needs to be done is to ascertain whether or not the mother is heterozygous for the major hemoglobinopathies. In the event that this is the case, the father ought to be screened as well. There is a twenty-five percent risk that the foetus is homozygous and has serious disease if he has the same abnormalities as the mother would have. It is recommended that these instances be directed to a facility that specialises in the treatment of hemoglobinopathies and provides prenatal counselling. DNA analysis and polymerase chain reaction (PCR) amplification can be used to make a prenatal diagnosis of hemoglobinopathy in the majority of instances. When a diagnosis of thalassemia major is made at an early stage, the parents have the opportunity to be presented with the choice of having an abortion.

Hemolytic Anaemias That Is Acquired

Antibodies that cause hemolytic anaemia

These types of anaemia are brought on by the production of autoantibodies that are directed against red cells, which then leads to the destruction of the red cells that have been coated with antibodies. There are two varieties of autoimmune hemolytic anaemias (AIHA): the warm type, which occurs when the antibody reacts most effectively at 37 degrees Celsius, and the cold type, which occurs when the antibody reacts most effectively at 4 degrees Celsius. There is evidence of the presence of antibodies (lgG, IgA, or IgM [immunoglobins]) or complement (C3, C3d) on the surface of red cells in both forms, as demonstrated by a positive direct antiglobulin test (DAT, Coombs test). Even if the DAT comes back negative, the diagnosis of AIHA is still possible because the antibody may have a low affinity for the target. On the other hand, a positive DAT not necessarily indicates the presence of an overt hemolytic anaemia in every single instance [43, 44]. It is possible for either type of AIHA to manifest as an acute or chronic problem, and it can also be idiopathic or due to other psychological conditions. In AIHA, the hemolysis that occurs is of the delayed kind. This means that the antibody-coated red cells go through the process of hemolysis in the reticuloendothelial system of the spleen.

AIHA of the Warm Variety

Although the disease is frequently idiopathic, it may also be linked to autoimmune disorders such as systemic lupus erythematosus, certain lymphomas, chronic lymphocytic leukaemia, and certain medications such as methyldopa, procainamide, and diclofenac, in addition to being connected with other diseases.

The Presentation of Clinicals

At any age, AIHA can manifest itself. It is possible for the severity of the hemolytic anaemia to vary. Patients may have jaundice, weariness, and dyspnea, and there is a possibility that the spleen will become enlarged. Patients may experience fever while they are experiencing an acute hemolytic crisis. There have been isolated instances in which autoimmune thrombopenic purpura, often known as Evan's syndrome, has been linked to AIHA.

Features of The Laboratory

The data from the laboratory seem to be consistent with a hemolytic anaemia. The blood film contains microspherocytes, which can be observed. When the DAT is positive, it is typically because of the presence of IgG ± complement on the red cells. The indirect antiglobulin test is another method that can be utilised to detect free antibody in the event that the autoantibody is produced in significantly high concentrations. Autoantibodies frequently exhibit blood group specificity, such as the ability to recognise Rh, Kidd, or LW antigens on red cells to name a few examples.

In the case of severe anaemia with symptoms, blood transfusions may be required as a treatment option. These transfusions should be administered in accordance with the same guidelines as are used for other anaemic patients. It is recommended that red cell concentrates that are negative for this antigen be transfused whenever it is practicable, provided that the specificity of the autoantibody is known. It is necessary to rule out the possibility of

alloantibodies being present, which could be the result of past transfusions or pregnancy. Because of the existence of autoantibodies, it is frequently challenging to locate red cell concentrates that are compatible with the patient. As a result, the blood that is the least incompatible is transfused, and after receiving informed consent and proper monitoring (in order to identify an acute hemolytic transfusion reaction), the blood is done. Treatment should be administered for any underlying cause of AIHA.

• Corticosteroids are the treatment of choice for adult-onset hepatitis A. The first dose of prednisone is between one and two milligrammes per kilogramme of body weight per day. This amount should be decreased with the clinical response. Certain individuals require a maintenance dose for a considerable amount of time. It is possible that some critically ill patients will require an increased dose of steroids at the beginning of their treatment (intravenous methylprednisone). Splenectomy is recommended for patients who are resistant to corticosteroids or who require a high maintenance dose. To determine whether or not a splenectomy would be successful, it may be beneficial to do a preoperative research using radioactively labelled red cells.

A medication that suppresses the immune system, such as cyclophosphamide, ciclosporine, or azathioprine, has the potential to improve hemolysis in patients who do not respond well to corticosteroids.

There is a possibility that high-dose immunoglobulins, which are treated in a manner comparable to that of idiopathic thrombocytopenic purpura (ITP; see page 272), could be beneficial in treating AIHA in certain instances.

This is the Cold Type of AIHA.

This illness may also be idiopathic, connected with infections (such as mycoplasma pneumonias or infectious mononucleosis), associated with lymphomas, or as a component of the cold agglutinin syndrome. In almost all cases, the antibody is IgM, and it reaches its optimal binding state at temperatures that are lower. An antibody will bind to the red cells after they have been exposed to low temperatures. This will activate the complement system, which will then begin the process of hemolysis. The reticuloendothelial system, which is most commonly seen in the liver, is responsible for phagocytosing the red cells, much as it is in warm-type AIHA.

Clinical Characteristics:

When exposed to cold temperatures, hemolytic crises and other clinical symptoms become more severe. When individuals are subjected to frigid temperatures, acrocyanosis is a common complication that arises. Additionally, presence of jaundice and splenomegaly is possible.

Features of The Laboratory:

Aside from the fact that the red cells have a tendency to agglutinate when exposed to cold temperatures, the laboratory characteristics are comparable to those of warm-type AIHA.

Anaemias of Hemolytic Origin Acquired

The cold autoantibodies may be monoclonal (in the case of cold agglutinin syndrome) or polyclonal (in cases associated with infections or low-grade lymphomas). Both types of autoantibodies are related with this condition. During the course of the cold agglutinin syndrome, it is possible to observe extremely high titers of the autoantibody.

Medical Care:

Avoiding exposure to cold temperatures is the primary method of treatment for this condition. Whenever it is possible to determine the underlying cause of the AIHA, it is imperative that this cause be treated. On rare occasions, corticosteroids and splenectomy are effective treatments. When the acute condition is really severe, plasmapheresis may be an effective method for halting the hemolysis. It is possible that immunosuppressive medications, such as chlorambucil or cyclophosphamide, will be beneficial in treating chronic instances. In cases of severe symptomatic anaemia, it is necessary to transfuse cleansed red cell concentrates in order to avoid the administration of extra complement. Use of a blood warmer is required in order to perform the transfusion. One of the causes of paroxysmal cold

hemoglobinuria is a biphasic IgG antibody, also known as the Donath Landsteiner antibody. This syndrome is seen in patients with tertiary syphilis as well as with youngsters who have recovered from a viral sickness. The symptoms of paroxysmal cold hemoglobinuria typically go away on their own.

Nocturnal Hemoglobinuria with Paroxysmal Symptoms

The condition known as paroxysmal nocturnal hemoglobinuria (PNH) is a clonal stem cell dysfunction that is acquired. PNH is characterised by the presence of faulty phosphatidyl-inositol-glycan (PIG) anchor molecules. The mutation of the PIG-A gene, which is located on the short arm of the X chromosome, has been identified as the molecular foundation for PNH that has been discovered. More than one hundred distinct mutations of the PIG-A gene have been identified up until this point. These variants include frameshift mutations, mis sense mutations, splicing defects, and other alterations. The deficiency of the anchor molecules may be present in all of the hematopoietic lines or it may be present in only some of them. CD59, decay accelerating factor (CD55), and C8 binding protein are some of the proteins that are attached to the cell membrane by this glycolipid anchor. These proteins play a key role in the control of complement components. In the event that these molecules are defective, the result is an increased susceptibility to complement-mediated lysis as well as a propensity for thrombosis. PNH cells are also deficient in the presence of other surface molecules, including CD14, CD24, and CD66. PNH is a very uncommon condition that can present itself as either pancytopenia or chronic hemolytic anaemia or both. The presence of red urine (hemoglobinuria) is something that some patients become aware of in the morning after experiencing hemolytic crises during the night. A number of recurrent thromboses, including those of the portal vein, cerebral vessels, or cutaneous veins, are among the most significant consequences. Portal vein thromboses are also included in this category. Anaemia caused by a lack of iron is frequently the result of a persistent loss of iron. A normochromic and normocytic anaemia is a condition that is frequently observed. Granulocytopenic and thrombocytopenic people are both present in some cases. There is a consistent presence of laboratory findings in conjunction with a chronic hemolytic anaemia. When either the acid hemolysis or the sucrose test turns out to be pathogenic (the addition of sucrose or acidified serum leads to greater in vitro hemolysis), a diagnosis of PNH can be made. Through the use of flow cytometry, it is possible to determine the degree to which anchor molecules are expressed in various cell compartments. Blood cells can be screened for the expression of CD55 or CD59, which is a simple diagnostic for pulmonary hypertension (PNH). With regard to the majority of patients, it is possible to differentiate between three distinct types of PNH cells: type III cells, which are completely devoid of GPI-anchored molecules; type II cells, which have a significantly diminished expression; and type I cells, which have maintained an approximately normal surface expression. The progression of PNH can lead to the development of other diseases, such as aplastic anaemia, myelodysplasia, and even acute leukaemia in rare cases. Conversely, PNH clones can be identified in a certain percentage of patients who have aplastic anaemia. Most of the treatment for PNH consists of supportive care. The patients should be given anticoagulants if they experience a high frequency of thromboses. It is recommended that thrombolysis and heparin be used in the treatment of a large thrombosis. It is recommended that iron and folic acid be substituted. In the event of a hemolytic crisis, it may be necessary to administer a pulse of corticosteroids. Regarding the therapy of PNH, danazol, which is an androgen derivative, is another option that can be examined. Donations of blood should be administered in the event that a clinical form of anaemia develops. PNH has a prognosis that is dependent on the severity of the condition. Cases that are not complicated may be able to live with the sickness for more than ten or fifteen years. It is possible that a bone marrow transplant from a sibling who shares the same HLA could be indicated in the event that PNH progresses

to progressive complications. This would provide the opportunity for a cure.

Diseases of the Newborn that are Hemolytic

The maternal alloimmunization that occurs as a result of blood group incompatibility between the mother and the foetus is the most common of the conditions that might lead to hemolytic disease of the newborn (HDN). HDN caused by ABO antibodies is the most common variety, although Rhesus (Rh) antibodies may be the cause of the most severe form of the disease.

AHDN ABO Antibodies was the cause.

ABO incompatibility plays a role in around two thirds of cases with HDN. An infant with the blood type A or B and a mother with a blood group of 0 is more likely to have the HDN predominance. There is a wide range of severity associated with the disease, with mild to moderate symptoms being seen in Caucasians, severe symptoms being seen in African and Chinese neonates, and around one third of the cases being witnessed in India. It is difficult to diagnose ABO HDN because the indirect antiglobulin test is typically negative or only weakly positive, and the estimation of lgG anti-A or anti-B is confounded by the presence of a substantial number of naturally existing IgM ABO antibodies. Both of these factors contribute to the difficulty of these diagnostic procedures. Prior to the estimation of anti-A or anti-B IgG, it is required to neutralise maternal serum with secretor saliva or to treat it with 2-mercaptoethanol or dithiotreitol. Both of these procedures are necessary.

Anaemias of Hemolytic Origin Acquired

The haemoglobin of the newborn is often normal, and reticulocytosis or normoblastosis are only seen in severe cases of the condition. ABO HDN that is mild to moderate can be treated with phototherapy, however infants who are seriously affected require an exchange transfusion when they are diagnosed.

AHDN the presence of Rhesus Antibodies

As a result of the availability of anti-D immunoglobulins for the purpose of prophylaxis, the Rh HDN has been nearly eradicated entirely. One of the prerequisites for Rh immunisation is the introduction of Rh (D)-positive erythrocytes into the maternal circulation. This is due to the fact that the Rh antigen is only found on human red cells. In certain instances, sensitization is brought on by a fetomaternal haemorrhage that occurs prior to completion of birth. However, even before the anti-D-prophylaxis was available, not all Rh-negative women who were exposed to Rh-positive erythrocytes became sensitised. This was the case even before the medication was available. The diagnosis of Rh HDN can be easily established when Rh (D) antibodies are found in the human serum and the antiglobulin test is positive on the foetal erythrocytes. This combination of findings is a diagnostic indicator. IgG antibodies produced by mothers are able to get through the placental barrier and coat Rh (D) positive red cells, hence shortening the lifespan of these cells. The greatest clinical manifestation of the disease is known as hydrops fetalis, and it manifests itself during the intrauterine life stage. In order to identify a badly damaged foetus and save it by intrauterine transfusion (lUT), antenatal examination is consequently something that is very necessary. These noninvasive parameters include periodic measures of Rh antibody levels and periodic ultrasonography examinations. Both of these parameters can be used to anticipate the severity of the condition. A spectroscopic examination of the amniotic fluid is beneficial, despite the fact that it requires amniocentesis, which is relatively safe when performed under the direction of ultrasonography. It is also feasible to take foetal blood in order to confirm the diagnosis of Rh HDN and to evaluate the severity of anaemia by calculating the haemoglobin and hematocrit levels. On the other hand, taking into account the dangers associated with this treatment, it need to be carried out only in cases when it is believed that the foetus is very unwell and requires an intrauterine device (IUT). When the mother has high titers of anti-D anti bodies, the amniotic fluid indicates growing bilirubin (Liley's zone II or III), and/or ultrasound reveals ascites, the intrauterine device (IUT) is typically planned. An intrauterine device (IUT) is carried out in the event that the haemoglobin concentration is seen to be more than two g/dL

lower than the normal value at the same age of gestation. An intrauterine device (IUT) can be administered as early as 18 weeks of gestation, and it must be repeated at intervals of one to three weeks. A simple transfusion may be required at delivery for foetuses that have undergone several intrauterine devices (IUTs), although in most cases, they do not require an exchange transfusion. inside the context of alloimmunization caused by Rh HDN, the induction of birth occurs after 32 or 34 weeks, depending on the resources that are accessible inside the intensive care unit. A preventive exchange transfusion may be necessary for infants who did not require an intravenous administration (IUT) shortly after birth. In the majority of cases of Rh HDN, phototherapy is used in order to convert bilirubin into a form that is less harmful. An exchange transfusion should always be performed in the event that hyperbilirubinemia is present at birth. This is done to reduce the possibility of permanent neurologic impairment, also known as kernicterus. HDN can also be caused by other antibodies, such as anti-Kell antibodies, however the severity of these effects is often less severe than Rh HDN. Management of these situations is contingent on the degree of severity that they present with .

here are a few distinct types of acquired hemolytic anaemia .

It is also possible for vascular alterations and a toxic alteration of the endothelium to produce a reduction in the survival time of red cells and an early termination of their hemolysis. In several of these conditions, an aberrant red cell morphology is observed (for example, fragmentocytes and schistocytes in a blood smear). Massive hemolytic anaemia can be brought on by a number of different illnesses, including malaria and babe siosis, for example. Toxins cause damage to the endothelium, which ultimately results in a microangiopathic hemolytic anaemia in patients with meningococcal sepsis .

Hemolysis Caused by Infections Caused by Parasites

In spite of the fact that malaria is uncommon in Western countries, it continues to be a significant public health concern in many other parts of the world. This viral cause of hemolytic anaemia poses a threat to those who are travelling to or living in the regions of sub-Saharan Africa, Central or South America, the Middle East, Southern Asia, or Polynesia. Plasmodium vivax, Plasmodium Jalciparum, Plasmodium malariae, and Plasmodium ovale are the four protozoan species that are responsible for the disease known as malaria. The saliva of the Anopheles mosquito is responsible for the transmission of these protozoans into the bloodstream of the insect's host. Initially, the parasites infect hepatocytes, which is where they multiply and grow into merozoites. They then enter the bloodstream as sporozoites and enter the bloodstream. Merozoites are able to re-enter the bloodstream, where they infect red blood cells, multiply asexually, and then emerge to infect more erythrocytes. It is essential to keep in mind that both P. vivax and P. ovale have the potential to remain alive in the liver in the form of latent forms, which can be reactivated at a later time. Malaria is characterised by a number of symptoms, including fever, chills, lethargy, and headaches. Patients who are infected with P. Jalciparum may also present with altered mental status, acute renal failure, respiratory distress, or gastroenteritis. These symptoms are in addition to the ones listed above. These clinical manifestations are caused by the propensity of red cells that are infected with P. Jalciparum to cling to endothelial cells of the vasculature and generate microvascular occlusions that are different from one another. If a patient is chronically infected or has P. Jalci parum, a physical examination may detect splenomegaly. This is especially true for patients who have chronic infection. The results of laboratory testing are outstanding in terms of identifying signs of extravascular hemolytic anaemia. In order to arrive at a diagnosis, a thick peripheral blood smear is examined to determine whether or not the parasites are present. The examination of the morphology of the organisms that are present on the slide assists in the identification of the specific species of Plasmodium. It is important to note that the

treatment for malaria is contingent upon the species of the parasite that causes the disease, the severity of the illness, and the chance that the organism is resistant to chloroquine. There is a possibility that chloroquine-sensitive malaria will continue to exist in the Caribbean, the Middle East, and Central America. Table 6.4 provides specific recommendations for the treatment of malaria as well as preventative actions that should be taken by travellers .

Anaemias of Hemolytic Origin Acquired

Babesiosis is a hemolytic anaemia that occurs when erythrocytes become infected with piriform protozoans, which are formed like pear-shaped spores. Babesia divergens and B. bovis, both of which are typically bovine parasites, are the organisms responsible for the disease in Europe. B. microti, a rodent parasite, is the organism that is responsible for the disease that is found on the east coast of the United States. On the west coast, a piroplasm that was just recently discovered and given the name WAI has been found in multiple cases. Ticks belonging to the genus Ixodes are used to transmit each and every one of these organisms. It is also possible for babesiosis to be passed on through blood transfusions. Babesiosis is often a benign condition that resolves on its own, but immunosuppressed patients, and particularly people who have had their spleens removed, are more likely to experience severe and sometimes fatal forms of the disease. At the time of presentation, these patients may be experiencing symptoms such as fevers, chills, headaches, weariness, myalgias, and arthralgias; however, further complications may include respiratory and renal failure. Icterus and mild splenomegaly may be brought to light during the physical examination. An extravascular hemolytic anaemia and, in many cases, thrombocytopenia are both indicators that are demonstrated by laboratory results. The presence of intraerythrocytic parasites can be identified by a thick smear of the peripheral blood, and the presence of an intracellular tetrad of merozoites is diagnostic of babesiosis at this stage. It is possible for sero logic testing to validate the diagnosis. For seven days, the treatment comprises of quinine sulphate 650 mg orally twice daily (TID) and clindamycin 600 mg orally three times daily (1200 mg intravenously twice daily). If the treatment is not finished, there is a possibility that a chronic carrier condition will be created .

There are microangiopathic anaemias .

Toxins cause damage to the endothelium in these disorders (hemolytic-uremic syndrome, thrombotic thrombocy, and topenic purpura), and the endothelium itself is killed along with any red cells or platelets that come into touch with it. It is possible that fragments of mentocytes are detected in the peripheral blood smear. After receiving a bone marrow transplant or after receiving certain medications (such as cyclosporine, cisplatin, or mitomycin C), patients may experience circumstances that are comparable to those described above.

Coagulation that is both disseminated and intravascular

A multitude of conditions can lead to the development of a condition known as disseminated intravascular coagulation (DIC), which is characterised by the activation of the coagulation cascades on a systemic level, which ultimately results in the accumulation of fibrin thrombi within the macrovascular system. Red cell fragmentation and intravascular hemolysis can be caused by a variety of different types of trauma incidents. It is possible for mechanical heart valves or prosthetic vascular devices to harm red blood cells that are located within the bloodstream. Also capable of inducing red cell fragmentation and hemolysis is the external stress that can be caused by prolonged marching or running, as well as playing bongo drums. A severe burn can cause damage to red blood cells in a direct manner. The condition known as lead poisoning is responsible for both sideroblastic anaemia and persistent hemolysis. Red cell hemolysis is also linked to copper toxicity, which can be caused by exposure to the metal in industrial settings or by Wilson's disease. During parenteral nutrition, for instance, hypophosphatemia might limit the amount of time that red cells are able to survive. Hemolysis can be

induced by being exposed to hypotonic liquids, such as when someone is on the verge of drowning. Enzymes that are generated by organisms that are clostridial Obtainable hemolytic anaemias have the potential to result in significant intravascular hemolysis. It is also possible for the membranes of red blood cells to be disrupted by the venom of certain spiders and snakes.

Conclusion:

IHAs that were caused by RBC membranopathy, RBC enzymopathy, and RBC hemoglobinopathy were screened and diagnosed using traditional methods such as RBC morphology, membrane protein analysis, Hb electrophoresis, and measurement of RBC enzyme levels. This process was carried out over the course of several years. The Sanger sequencing technique became important throughout the genetic age for identifying genetic variants that are responsible for causing IHAs. We were able to improve our ability to identify the many genetic abnormalities that can lead to IHAs as a result of recent advancements in genetic technology that utilised NGS. A wide range of aetiologies and clinical manifestations are associated with hemolytic anaemias, which can have acquired or inherited origins in children. A thorough study of one's own and one's family's medical history, as well as a synthesis of the results of the physical examination and laboratory tests, are always essential for differential diagnosis. Hereditary hemolytic anaemias are a public health concern that receives attention, particularly in communities where marriages between members of the same family are extremely common. As a result, medical professionals must to be knowledgeable with the many techniques of preventive and early diagnosis signs. The use of next-generation sequencing (NGS) and associated genetic studies in clinical laboratories will make it possible to make an accurate diagnosis of intrahepatic aortic aneurysm (IHA). This will allow for the elimination of inconclusive and less reliable morphologic and biochemical examination. We are of the opinion that gaining an understanding of IHA on a genetic foundation and implementing genetic technology for routine clinical laboratory testing would not only increase the accuracy and efficiency of IHA diagnosis, but will also provide us with insights that will allow us to practise precision medicine on each individual who is affected.

References:

1. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
2. Iolascon A, Miraglia del Giudice E, Perrotta S, et al. Hereditary spherocytosis: from clinical to molecular defects. Haematologica 1998;83:240-257. Olivieri NF, Brittenham GM. lron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
3. Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine 1997;76:63-93. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1027-1030. Weatherall DJ. The hereditary anemias. Br Med J 1997;314:492-496.
4. Jacobasch G, Rapoport SM. Hemolytic anemias due to erythrocyte enzyme deficiencies. Mol Aspects Med 1996;17: 143-70.
5. Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol 2005;130:11-25.
6. Parker CJ. Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 2012;19:141-8. 8. Gallagher PG. Diagnosis and management of rare congenital nonimmune hemolytic disease. Hematology Am Soc Hematol Educ Program 2015;2015:392-9.
7. Park ES, Jung HL, Kim HJ, et al. Hereditary hemolytic anemia in Korea from 2007 to 2011: A study by the Korean Hereditary Hemolytic Anemia Working

Party of the Korean Society of Hematology. Blood Res 2013;48:211-6.

8. Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers 2015;2015:635670. 11. King MJ, Zanella A. Hereditary red cell membrane disorders and laboratory diagnostic testing. Int J Lab Hematol 2013;35:237-43.
9. Christensen RD, Nussenzveig RH, Yaish HM, Henry E, Eggert LD, Agarwal AM. Causes of hemolysis in neonates with extreme hyperbilirubinemia. J Perinatol 2014;34:616-9.
10. van der Harst P, Zhang W, Mateo Leach I, et al. Seventy-five genetic loci influencing the human red blood cell. Nature 2012;492:369-75.
11. Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ; General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis and management of hereditary spherocytosis-2011 update. Br J Haematol 2012;156:37-49.
12. Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica 2012;97:516-23.
13. King MJ, Garçon L, Hoyer JD, et al. ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders. Int J Lab Hematol 2015;37:304-25.
14. King MJ, Behrens J, Rogers C, Flynn C, Greenwood D, Chambers K. Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. Br J Haematol 2000;111:924-33.
15. Farias MG. Advances in laboratory diagnosis of hereditary spherocytosis. Clin Chem Lab Med 2017;55:944-8.
16. Frickhofen N, Chen ZJ, Young NS, Cohen BJ, Heimpel H, Abkowitz JL. Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994;87:818-24.
17. Hassoun H, Vassiliadis JN, Murray J, et al. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997;90:398-406.
18. Mariani M, Barcellini W, Vercellati C, et al. Clinical and hematologic features of 300 patients affected by hereditary spherocytosis grouped according to the type of the membrane protein defect. Haematologica 2008;93:1310-7.
19. Delaunay J. The molecular basis of hereditary red cell membrane disorders. Blood Rev 2007;21:1-20.
20. Iolascon A, Miraglia del Giudice E, Perrotta S, Alloisio N, Morlé L, Delaunay J. Hereditary spherocytosis: from clinical to molecular defects. Haematologica 1998;83:240-57.
21. Eber SW, Gonzalez JM, Lux ML, et al. Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis. Nat Genet 1996;13:214-8.
22. Eber S, Lux SE. Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer. Semin Hematol 2004;41:118-41.
23. Park J, Jeong DC, Yoo J, et al. Mutational characteristics of ANK1 and SPTB genes in hereditary spherocytosis. Clin Genet 2016;90:69-78.
24. Da Costa L, Galimand J, Fenneteau O, Mohandas N. Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Rev 2013;27:167-78.

25. Glele-Kakai C, Garbarz M, Lecomte MC, et al. Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin. Br J Haematol 1996;95: 57-66.

26. Dhermy D, Schrével J, Lecomte MC. Spectrin-based skeleton in red blood cells and malaria. Curr Opin Hematol 2007;14:198- 202.

27. Gallagher PG, Weed SA, Tse WT, et al. Recurrent fatal hydrops fetalis associated with a nucleotide substitution in the erythrocyte beta-spectrin gene. J Clin Invest 1995;95:1174-82.

28. Hirtz D, Kirkham FJ. Sickle cell disease and stroke. Pediatr Neurol 2019; 95: 34-41. 14. Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers 2018; 4: 18010.

29. Sant'Ana PG, Araujo AM, Pimenta CT, et al. Clinical and laboratory profile of patients with sickle cell anemia. Rev Bras Hematol Hemoter 2017; 39: 40-5.

30. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014; 312: 1033-48.

31. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020; 4: 327-55.

32. Antmen B, Karakaş Z, Yeşilipek MA, et al. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Türkiye (REACH-THEM). Eur J Haematol 2019; 102: 123-30.

33. Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. Am J Hematol 2019; 94: 55-61.

34. Herity LB, Vaughan DM, Rodriguez LR, Lowe DK. Voxelotor: a novel treatment for sickle cell disease. Ann Pharmacother 2021; 55: 240-5.

35. Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med 2018; 379(3): 226-35.

36. Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: An update. Cytotherapy 2018; 20: 899-910.

37. Cho HS, Hah JO, Kang IJ, et al. Hereditary hemolytic anemia in Korea: a retrospective study from 1997 to 2006. Korean J Hematol 2007;42:197-205.

38. Han E, Kim A, Park J, et al. Spectrin Tunis (Sp alpha (I/78)) in a Korean family with hereditary elliptocytosis. Ann Lab Med 2013;33:386-9.

39. Hoffman R, Benz EJ Jr, Silberstein LE, Heslop H, Weitz J, Anastasi J. Hematology: basic principles and practice. 6th ed. Philadelphia, PA: Elsevier Saunders, 2013:418-26.

40. Niss O, Chonat S, Dagaonkar N, et al. Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood Cells Mol Dis 2016;61:4-9.

41. Prchal JT, Gregg XT. Red cell enzymes. Hematology Am Soc Hematol Educ Program 2005:19-23.

42. Koralkova P, van Solinge WW, van Wijk R. Rare hereditary red blood cell enzymopathies associated with hemolytic anemia - pathophysiology, clinical aspects, and laboratory diagnosis. Int J Lab Hematol 2014;36:388-97.

43. Vives i Corrons JL. Chronic non-spherocytic haemolytic anaemia due to congenital pyrimidine 5' nucleotidase deficiency: 25 years later. Baillieres Best Pract Res Clin Haematol 2000;13:103-18.

44. Kahn A, Kaplan JC, Dreyfus JC. Advances in hereditary red cell enzyme anomalies. Hum Genet 1979;50:1-27.
45. Fiorelli G, Martinez di Montemuros F, Cappellini MD. Chronic non-spherocytic haemolytic disorders associated with glucose6-phosphate dehydrogenase variants. Baillieres Best Pract Res Clin Haematol 2000;13:39-55.
46. Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Pyruvate kinase deficiency: the genotype-phenotype association. Blood Rev 2007;21:217-31.
47. Canu G, De Bonis M, Minucci A, Capoluongo E. Red blood cell PK deficiency: An update of PK-LR gene mutation database. Blood Cells Mol Dis 2016;57:100-9.